reports
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Thomas Couvreur
- Wim Lewi
Corbion reports the progress of its share buyback program 22 September...
Corbion reports the progress of its share buyback program 22 September – 26 September 2025 Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 22 September up to and including 26 September 2025 a total of 57.112 shares were repurchased at an average price of €16.756 for a total amount of €956,979.58 To date, the total consideration for shares repurchased amounts to €3,551,493.30 representing 35.51% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the pro...
- ING Helpdesk
Benelux Morning Notes
Belgian telecoms: Telenet increases its fixed internet speed at unchanged price Colruyt: FY25/26F profitability guidance maintained despite market share loss Corbion: Keep Calm and Carry On Fagron: Acquires UCP, adding to its 503A health and wellness offering in California GBL: Planning ahead to deliver on its promise OCI: Limited details on Orascom merger, sales process for Nitrogen Europe ongoing TKH Group: Mixed emotions Wolters Kluwer: Launches UpToDate Expert AI
- Jacob Mekhael
- Mathijs Geerts Danau
Life Sciences Conference 25 Sep 2025
KBC Securities will host its annual life sciences conference on 25 September in Brussels. The event will include 14 exciting companies, both public and private, from the BeNeLux ecosystem and beyond. In this conference note, we provide an overview of the attending companies, as well as an outlook on KBC Securities' life sciences broader coverage.
Corbion reports the progress of its share buyback program 15 September...
Corbion reports the progress of its share buyback program 15 September – 19 September 2025 Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 15 September up to and including 19 September 2025 a total of 37.260 shares were repurchased at an average price of €17.0780 for a total amount of €636,327.91 To date, the total consideration for shares repurchased amounts to €2,594,512.93 representing 25.95% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the pr...
- Guy Sips
- Hilde Van Boxstael
- Livio Luyten
- Michiel Declercq
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Onward Medical Publishes ARCIM data on blood pressure regulation in Na...
Onward announced two publications of detailed results from the clinical feasibility studies of ARC-IM therapy in blood pressure regulation in Nature and Nature Medicine. The publications build on the previously reported interim results, and continue to highlight the benefit of the ARC-IM system for SCI patients that have blood pressure instability. Note that ARC-IM for blood pressure instability is the next in line indication for Onward, where a pivotal (Empower BP) study is due to start by YE25...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Lynn Hautekeete
- Mathijs Geerts Danau
- Michiel Declercq
Concurrent Publications in Nature and Nature Medicine Highlight Advanc...
Concurrent Publications in Nature and Nature Medicine Highlight Advances in Blood Pressure Regulation after Spinal Cord Injury Using ONWARD ARC-IM Therapy Detailed results from clinical feasibility studies show immediate improvement in blood pressure stability and durable reduction of hypotensive symptoms, resulting in improved quality of life Most people living with spinal cord injury experience blood pressure instability, which represents a key unmet needToday’s concurrent publications provide clinical evidence for ARC-IM® Therapy ahead of the Company’s planned initiation of the Empowe...
Corbion reports the progress of its share buyback program 8 September ...
Corbion reports the progress of its share buyback program 8 September – 12 September 2025 Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 8 September up to and including 12 September 2025 a total of 28.805 shares were repurchased at an average price of €17.4190 for a total amount of €501,753.53 To date, the total consideration for shares repurchased amounts to €1,985,185.01 representing 19.58% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the prog...
- ING Helpdesk
Benelux Morning Notes
Azelis: Highlights ING Benelux Conference London. Barco: Highlights ING Benelux Conference London. Kinepolis: Highlights ING Benelux Conference London. Melexis: Highlights ING Benelux Conference London. ABN AMRO: Dutch State reducing stake to 20%. ASML: x Mistral, a bet on A.I.. Kinepolis: Cineplex August 2025 box office revenue at 87% of 2019 level, down 27% YoY
- Jacob Mekhael
Onward Medical Receives CE Mark certification for ARC-EX in the EU
Onward announced it has received CE Mark certification for its ARC-EX System under the European Union Medical Device Regulation (MDR), enabling commercialisation in the European Union and certain other countries. We note the label includes home use as well as clinic use which is an important driver for broader commercial uptake. Onward plans to begin EU launch in the coming weeks, starting with Germany. From our conversations with management, we don't expect a significant delta on EU pricing vs....
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Wim Lewi
ONWARD Medical Receives CE Mark for ARC-EX, Enabling Commercial Launch...
ONWARD Medical Receives CE Mark for ARC-EX, Enabling Commercial Launch of Breakthrough Spinal Cord Stimulation System in Europe THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The CE Mark certification allows marketing for both clinic and home useFirst commercial sales of the ARC-EX® System in Europe are expected in Q4 2025The CE Mark enables commercialization in the European Union and facilitates a streamlined regulatory pathway in other countries, including in the UK and Switzerland EINDHOVEN, the Nethe...
Corbion reports the progress of its € 10 million share buyback program...
Corbion reports the progress of its € 10 million share buyback program 1 September – 5 September 2025 Corbion hereby reports the transaction details related to its € 10 million share buyback program announced on 1 September 2025. During the week of 1 September up to and including 5 September 2025 a total of 83,962 shares were repurchased at an average price of €17.3463 for a total amount of €1,456,431.48. To date, the total consideration for shares repurchased amounts to €1,456,431.48 representing 14.56% of the overall share buyback program. Corbion publishes on a weekly basis every Mond...
- Hilde Van Boxstael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Jacob Mekhael
Onward Medical 1H25 update shows ARC-EX launch on track, home use labe...
Onward reported 1H25 results demonstrating positive execution with the company achieving its internal target of selling 30 devices as part of the planned phased launch of the ARC-EX device in the US. We are encouraged to learn that the company expects continued demand for the remainder of the year to meet its FY25 targets (KBCSe: 193 devices). Timelines were reiterated, and we look forward to the home use label expected by YE25, which we view as an important driver for broader commercial uptake ...
- Jacob Mekhael
- Livio Luyten
- Thomas Couvreur
ONWARD Medical Demonstrates Commercial Traction and Advances Pipeline ...
ONWARD Medical Demonstrates Commercial Traction and Advances Pipeline in the First Half of 2025 THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, The Netherlands, Sept. 02, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces its results for the first half of 2025: Commercial ...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.